Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?

BMC Psychiatry

Research Article

Patrick Dicker¹  Melanie Föcking²  Lorna M. Lopez²  David R. Cotter³  Mary Cannon³  Stefan Smesny⁴  Patrick D. McGorry⁵  G. Paul Amminger⁵  Miriam R. Schäfer⁵ 

[1] Department of Epidemiology and Public Health, Royal College of Surgeons in Ireland, Dublin, Ireland;Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland;Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland;Department of Psychiatry, Beaumont Hospital, Dublin, Ireland;Department of Psychiatry, University Hospital Jena, Jena, Germany;Orygen, The National Centre of Excellence in Youth Mental Health, The University of Melbourne Centre for Youth Mental Health and Melbourne Health, Parkville, VIC, Australia;

关键词: Plasma;    At-risk mental state;    IL12/IL23p40;    Omega-3;    Inflammation;    Biomarker;    Psychosis;   

DOI  :  10.1186/s12888-016-1039-7

 received in 2015-09-03, accepted in 2016-09-09,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe identification of biomarkers of transition from the at-risk mental state (ARMS) to psychotic disorder is important because early treatment of psychosis is associated with improved outcome. Increasing evidence points to an inflammatory contribution to psychosis.We questioned whether raised levels of plasma inflammatory markers predict transition from ARMS to psychotic disorder and whether any such predictors could be reduced by omega-3 (ω-3) polyunsaturated fatty acids (PUFAs).MethodsWe measured the levels of 40 neuroinflammation biomarkers using a commercially available immunoassay kit. Firstly, we compared inflammatory markers in subjects in the ARMS who transitioned to psychotic disorder (n = 11) compared to subjects who did not (n = 28). Then we compared inflammatory markers in all subjects before and after ω-3 PUFA treatment (n = 40).ResultsOur data provides preliminary evidence that elevations in the baseline plasma levels of the inflammatory marker IL12/IL23p40 are associated with transition from ARMS to psychotic disorder. IL12/IL23p40 levels did not change following 12 weeks administration of ω-3 PUFAs. These findings provide evidence that elevated plasma IL12/IL23p40 is a potential biomarker of increased risk for transition to psychotic disorder.ConclusionFurther studies are required to confirm and extend this finding. Our results do not provide support for the possibility that administration of ω-3 PUFAs act to reduced transition to psychotic disorder by reducing blood levels of IL12/IL23p40.Trial registrationClinicalTrials.gov, a service of the U.S. National Institutes of Health, Identifier: NCT00396643, last updated December 20, 2007. Retrospectively registered.

【 授权许可】

CC BY   
© The Author(s). 2016